Demographic Characteristics of COVID-19 Patients in District Gujrat
Objective: To determine the prevalence of Covid-19 in the district of Gujrat, its association with gender, age, its correlation with respiratory and cardiac symptoms and to find the link of this disease with travel history of patients to affected areas.
Methodology: A total of 222 COVID-19 -Positive patients (Male and Female) out of 514 clinically suspected cases (fever, cough, dyspnoea, lethargy & anosmia) as per WHO guidelines were selected. The use of the data for research purposes was explained to patients, and informed consent was taken. The study was approved by the ethical committee of Aziz Bhatti Shaheed Hospital. Samples were extracted from nasopharyngeal swabs using standard extraction protocol. Statistical tools used was SPSS Version 24. Chi-square test and correlation of age with respiratory and cardiac symptoms was calculated.
Results: Male gender was significantly affected by this disease (P=0.001) as compared to the female gender. Regarding the prevalence of respiratory symptoms, 31(14%) were asymptomatic. 37(16.7%) had Dyspnea, 45 (65.3%) cough (P= 0.001). Nine (4.1%) developed pneumonia. Fever and Cough was the most common symptom in the age group 21-40 yrs(P=0.001). While pneumonia developed in the older age group. The cardiac symptoms appeared in young age group (p=0.000) in the age group 21-40 yrs (70.9% n=78).38 patients (17.2%) had the symptom of chest pain, 24(10.9%) tachycardia and 1(0.5%) developed arrhythmia. Out of 222 COVID positive patients, 67.1% (149) gave a history of direct contact with positive patients, 19.8% (n=44) gave travel history,4.5% (n=10) had a history of going to Raiwind Ijtamah and 8.6% (n=19) were zaireen/pilgrims from Taftan.
Conclusion: The COVID -19 is comparatively more common in male patients. 50% of the patients were of age group 21-40 years showing the symptoms of fever and cough along with mild cardiac symptoms. Acute pneumonia developed in older age groups while cardiac symptoms were significant in young age. In Gujrat District, the majority of the patients (67.1%) developed Covid-19 due to travelling.
2. Liang Y, Liang J, Zhou Q, Li X, Lin F, Deng Z, et al. Prevalence and clinical features of 2019 novel coronavirus disease (COVID-19) in the Fever Clinic of a teaching hospital in Beijing: a single-center, retrospective study. medRxiv. 2020;2020.02.25.20027763.
3. Berlin I, Thomas D, Le Faou AL, Cornuz J. COVID-19 and smoking. Nicotine Tob Res. 2020;1–3.
4. Yanping Zhang. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team (China Centre for Disease Control). The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases(COVID-19) in China. China CDC Wkly 2020; 41: 145–51.
5. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of COVID-19 disease. medRxiv. 2020;
6. Chan JFW, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020; 395: 514–23. 17
7. Xu X, Wu X, Jiang X, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. Bmj 2020; 368: m606
8. Jernigan DB, CDC COVID-19 Response Team. Update: Public Health Response to the Coronavirus Disease 2019 Outbreak - United States, February 24, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 216–9.
9. Bernard Stoecklin S, Rolland P, Silue Y, et al. First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020. Euro Surveill 2020; 25. DOI:10.2807/1560-7917.ES.2020.25.6.2000094.
10. Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. (2003) 348:1967–76. doi: 10.1056/NEJMoa 03074
11. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. (2012) 367:1814–20. doi: 10.1056/NEJMoa 1211721
12. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with Pneumonia in China, 2019. N Engl J Med. (2020) 382:727–33. doi: 10.1056/NEJMoa2001017
13. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. (2020) 382:1199–207. doi: 10.1056/NEJMoa 2001316
14. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-toperson transmission: a study of a family cluster. Lancet. (2020) 395:514–23. doi: 10.1016/S0140-6736(20)30154-9
15. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. (2020) 395:497–506. doi: 10.1016/S0140-6736(20) 30183-5
16. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. (2020) 395:507–13. doi: 10.1016/S0140-6736(20)30211-7
17. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China. Allergy. (2020). doi: 10.1111/all.14238. [Epub ahead of print].
18. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. (2020). doi: 10.1001/jama.2020.1585. [Epub ahead of print].
19. Jin J-M, Bai P, He W, Wu F, Liu X-F, Han D-M, Liu S and Yang J-K (2020).Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. Front. Public Health 8:152. doi: 10.3389/fpubh.2020.00152
20. Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med. (2006) 23:623–8. doi: 10.1111/j.1464-5491.2006.01861.x
21. National Health Commission of PRC. Daily Briefing on Novel Coronavirus Cases in China. (2020). Available online at: http://ennhcgovcn/2020-02/23/c_76779htm
22. Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptordamages islets and causes acute diabetes. Acta Diabetol. ( 2010) 47:193–9. doi: 10.1007/s00592-009-0109-4
23. Patel SK, Velkoska E, Burrell LM. Emerging markers in cardiovascular disease: where does angiotensin-converting enzyme 2 fit in? Clin Exp Pharmacol Physiol. (2013) 40:551–9. doi: 10.1111/1440-1681.12069
24. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clinical Research in Cardiology. 2020.
25. Wu JT, Leung K, Bushman M, Kishore N, Niehus R, de Salazar PM, et al. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nat Med [Internet]. 2020;26(4):506–10. Available from: http://dx.doi.org/10.1038/s41591-020-0822-7
26. Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19) [Internet]. Vol. 46, Intensive Care Medicine. Springer Berlin Heidelberg; 2020. 854–887 p. Available from: https://doi.org/10.1007/s00134-020-06022-5
Copyright (c) 2020 Hussnain Ashraf Gondal, Hassan Mumtaz, Irfan Afzal Mughal, Noor-ul-Ain Irfan, Shamim Mumtaz, Asma Irfan
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
All research articles published in the Journal of Rawalpindi Medical College (JRMC) are fully open access: immediately freely available to read, download, and share. Copyrights of all articles published in JRMC are retained by the authors. First publication rights are granted to JRMC. The journal/publisher is not responsible for subsequent uses of the work.
All articles are published under the Creative Commons Attribution (CC BY-SA 4.0) license.